UTHealth-CRU at M. D. Anderson Cancer Center, Houston
The CCTS CRU activities at M. D. Anderson Cancer Center comprise the Clinical and Translational Research Center (CTRC) and the Phase I Clinical Trials Program in the Department of Investigational Cancer Therapeutics.
Clinical and Translational Research Center (CTRC)
Director: Daniel D. Karp, MD
Contact person: Brenda Brown, RN, MSN, OCN
The CTRC is a 6,500 sq. ft., 15-room (16-bed) outpatient unit dedicated to innovative clinical research and new drug development. The unit began operations in 2002 and is located on the 10th floor of M. D. Anderson’s Clark Clinic Building. The CTRC provides sophisticated nursing care; phlebotomy services for pharmacokinetic studies; pharmacy services; a laboratory for specimen collection, preparation, and storage; and administration of therapy for clinical research studies. Assistance with development of clinical protocols and their budgets is also available. The unit is open 24 hours a day Monday through Friday and by appointment on weekends. The CTRC gives priority to Phase I and Phase II studies, but other studies can be conducted in the unit.
For more information or to use the CTRC, please contact Monica Wyles (email@example.com) 713-563-0359
Phase I Clinical Trials Program in the Department of Investigational Cancer Therapeutics
Director: Dr. Funda Meric-Bernstam
Contact person: Maryam Daneshmand, MHA
The Phase I Clinical Trials Program in the Department of Investigational Cancer Therapeutics consists of clinical and translational scientists, research nurses, study coordinators, clinical research fellows, and others who develop and perform innovative early clinical trials. The program emphasizes novel agents, unique studies, and hypothesis-driven clinical research. The program’s mission is to be a resource for the performance and coordination of high-impact, innovative Phase I trials. Although many Phase I and Phase I/II trials are sponsored by the pharmaceutical industry, early trials are a financial gamble for pharmaceutical companies, and many prefer to concentrate on studies of agents with proven efficacy that will soon yield a financial return. Identifying small subgroups of patients as responders and studying uncommon diseases and mechanism of drug action often require pioneering technologies and investigator-initiated endeavors. In addition, some Phase I trials for complex diseases must involve new combinations of approved or experimental drugs, and if the drugs are manufactured by different companies, the companies can be loath to invest in trials of drug regimens that include their competitors’ products. This, combined with the industry’s preference to fund trials for common diseases, hinders the implementation of the most innovative early clinical trials. The Phase I Clinical Trials Program was instituted to overcome these barriers and so to identify as rapidly as possible the best possible treatments for complex diseases. The group meets weekly to discuss current trials in the program and to enroll patients who might benefit from participating in a trial. At the end of a trial, plans are made to assure that progression to Phase II occurs in a rapid and seamless fashion.
For more information on the Phase I Clinical Trials Program or to find out how to participate, please contact Maryam Daneshmand, MHA (firstname.lastname@example.org) 713-794-4289.
6411 Fannin St., RPV 314
1515 Holcombe Blvd - Unit 367
5656 Kelley Street
800 West Jefferson St. , Edelstein Building, Suite 230
CLINICAL TRIALS RESOURCE CENTER | BERD | REDCap
COMMITTEE FOR THE PROTECTION OF HUMAN SUBJECTS | ANIMAL RESEARCH | ENVIRONMENTAL HEALTH & SAFETY | CORE LABORATORIES | SPONSORED PROJECTS | TECHNOLOGY MANAGEMENT | OFFICE OF RESEARCH